Trial · NCT05050942
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
NCT05050942, Phase 3, Active not recruiting, Camurus AB
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET. Trials, record NCT05050942. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05050942
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
- NCT number
- NCT05050942
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 332 participants, actual
- Lead sponsor
- Camurus AB
- Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor
- Interventions
- CAM2029, Octreotide LAR, Lanreotide ATG
- First posted
- 2021-09-21
- Last updated
- 2026-07-28
- Other registries' IDs
- eudract:2021-000849-40
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) as assessed by a Blinded Independent Review Committee (BIRC) | From date of randomization until disease progression or death due to any cause, whichever comes first, assessed up to 48 months | PFS is defined as time from the date of randomization to the date of the first documented disease progression as per RECIST 1.1 or death due to any cause (whichever occurs first) |
| Secondary | Overall survival | Up to 2 years following the primary efficacy analysis | The time from the date of randomization to the date of death due to any cause |
| Secondary | PFS as assessed by local Investigators | From date of randomization until disease progression or death due to any cause, whichever comes first, assessed up to 48 months | PFS is defined as time from the date of randomization to the date of the first documented disease progression as per RECIST 1.1 or death due to any cause (whichever occurs first) |
| Secondary | Overall response rate | From date of randomization until disease progression, assessed up to 48 months | The proportion of patients with best overall response of complete response (CR) or partial response (PR), as per BIRC according to RECIST 1.1 |
| Secondary | Disease control rate | From date of randomization until disease progression, assessed up to 48 months | The proportion of patients with a best overall response of CR, PR or stable disease (SD), as per BIRC according to RECIST 1.1 |
| Secondary | Time to tumor response | From date of randomization until disease progression, assessed up to 48 months | The time from the date of randomization to the first documented response of CR or PR, as per BIRC according to RECIST 1.1 |
| Secondary | Duration of response | From date of randomization until disease progression or death due to underlying cancer, whichever comes first, assessed up to 48 months | The time from the date of the first documented response of CR or PR to the date of the first documented progression or death due to underlying cancer, as per BIRC according to RECIST 1.1 |
| Secondary | Incidence of treatment-emergent adverse events | From screening to the safety follow-up, assessed up to 6 years |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38229199 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05050942
GET https://conductscience.org/api/trials/v1/NCT05050942/registered